Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12587803,unbound fractions,"Protein binding was minimal in both milk and plasma, with unbound fractions of 1 and 0.84, respectively There was little partitioning into milk fat, as demonstrated by the whole milk:skim milk ratio of 0.98.",Hydromorphone transfer into breast milk after intranasal administration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587803/),,1,287,DB00327,Hydromorphone
,12587803,unbound fractions,"Protein binding was minimal in both milk and plasma, with unbound fractions of 1 and 0.84, respectively There was little partitioning into milk fat, as demonstrated by the whole milk:skim milk ratio of 0.98.",Hydromorphone transfer into breast milk after intranasal administration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587803/),,0.84,288,DB00327,Hydromorphone
,12587803,M:P ratios,"The observed and predicted M:P ratios +/- SD for hydromorphone were 2.57 +/- 0.47 and 1.11 +/- 0.28, respectively.",Hydromorphone transfer into breast milk after intranasal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587803/),,2.57,289,DB00327,Hydromorphone
,12587803,M:P ratios,"The observed and predicted M:P ratios +/- SD for hydromorphone were 2.57 +/- 0.47 and 1.11 +/- 0.28, respectively.",Hydromorphone transfer into breast milk after intranasal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12587803/),,1.11,290,DB00327,Hydromorphone
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,30,3433,DB00327,Hydromorphone
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,54,3434,DB00327,Hydromorphone
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,67,3435,DB00327,Hydromorphone
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,82,3436,DB00327,Hydromorphone
,22169470,maximum hydromorphone plasma concentration (C(max)),"The obtained main pharmacokinetic parameters of hydromorphone in postoperative patients were as follows: the maximum hydromorphone plasma concentration (C(max)) was (24.15 ± 12.51)ng/mL, the time to the C(max) was (10.0 ± 0.0)min, and the elimination half-life was (2.7 ± 0.8)h.",Determination of hydromorphone in human plasma by a sensitive RP-HPLC-ESI-MS method and its application to a clinical pharmacokinetic study in postoperative patients after low dose intravenous administration with infusion pump. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169470/),[ng] / [ml],24.15,6633,DB00327,Hydromorphone
,22169470,time to the C(max),"The obtained main pharmacokinetic parameters of hydromorphone in postoperative patients were as follows: the maximum hydromorphone plasma concentration (C(max)) was (24.15 ± 12.51)ng/mL, the time to the C(max) was (10.0 ± 0.0)min, and the elimination half-life was (2.7 ± 0.8)h.",Determination of hydromorphone in human plasma by a sensitive RP-HPLC-ESI-MS method and its application to a clinical pharmacokinetic study in postoperative patients after low dose intravenous administration with infusion pump. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169470/),min,10.0,6634,DB00327,Hydromorphone
,22169470,elimination half-life,"The obtained main pharmacokinetic parameters of hydromorphone in postoperative patients were as follows: the maximum hydromorphone plasma concentration (C(max)) was (24.15 ± 12.51)ng/mL, the time to the C(max) was (10.0 ± 0.0)min, and the elimination half-life was (2.7 ± 0.8)h.",Determination of hydromorphone in human plasma by a sensitive RP-HPLC-ESI-MS method and its application to a clinical pharmacokinetic study in postoperative patients after low dose intravenous administration with infusion pump. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169470/),h,2.7,6635,DB00327,Hydromorphone
>,11868970,extraction recoveries,The extraction recoveries were > 76% for all analytes.,LC-MS-MS analysis of hydromorphone and hydromorphone metabolites with application to a pharmacokinetic study in the male Sprague-Dawley rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868970/),%,76,11390,DB00327,Hydromorphone
,11868970,limits of detection,"Using a plasma sample size of 100 microl, the limits of detection were 7.0 nmol(-1) (2.0 ng ml(-1)) for hydromorphone, dihydromorphine and dihydroisomorphine and 11 nmol l(-1) (5.0 ng ml l(-1)) for hydrormorphone-3-glucuronide, dihydromorphine-3-glucuronide and dihydroisomorhine-3-glucuronide at a signal-to-noise ratio = 3. 3.",LC-MS-MS analysis of hydromorphone and hydromorphone metabolites with application to a pharmacokinetic study in the male Sprague-Dawley rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868970/),1/[nmol],7.0,11391,DB00327,Hydromorphone
,11868970,limits of detection,"Using a plasma sample size of 100 microl, the limits of detection were 7.0 nmol(-1) (2.0 ng ml(-1)) for hydromorphone, dihydromorphine and dihydroisomorphine and 11 nmol l(-1) (5.0 ng ml l(-1)) for hydrormorphone-3-glucuronide, dihydromorphine-3-glucuronide and dihydroisomorhine-3-glucuronide at a signal-to-noise ratio = 3. 3.",LC-MS-MS analysis of hydromorphone and hydromorphone metabolites with application to a pharmacokinetic study in the male Sprague-Dawley rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868970/),[ng] / [ml],2.0,11392,DB00327,Hydromorphone
,11868970,limits of detection,"Using a plasma sample size of 100 microl, the limits of detection were 7.0 nmol(-1) (2.0 ng ml(-1)) for hydromorphone, dihydromorphine and dihydroisomorphine and 11 nmol l(-1) (5.0 ng ml l(-1)) for hydrormorphone-3-glucuronide, dihydromorphine-3-glucuronide and dihydroisomorhine-3-glucuronide at a signal-to-noise ratio = 3. 3.",LC-MS-MS analysis of hydromorphone and hydromorphone metabolites with application to a pharmacokinetic study in the male Sprague-Dawley rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868970/),[nM] / [l],11,11393,DB00327,Hydromorphone
,11868970,signal-to-noise ratio,"Using a plasma sample size of 100 microl, the limits of detection were 7.0 nmol(-1) (2.0 ng ml(-1)) for hydromorphone, dihydromorphine and dihydroisomorphine and 11 nmol l(-1) (5.0 ng ml l(-1)) for hydrormorphone-3-glucuronide, dihydromorphine-3-glucuronide and dihydroisomorhine-3-glucuronide at a signal-to-noise ratio = 3. 3.",LC-MS-MS analysis of hydromorphone and hydromorphone metabolites with application to a pharmacokinetic study in the male Sprague-Dawley rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868970/),,3. 3,11394,DB00327,Hydromorphone
,2445789,absolute bioavailability,"Hydromorphone has an absolute bioavailability of 51.35 +/- 29.29% and 36.33 +/- 29.60% after peroral and rectal administration, respectively.",Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plasma ratio and clinical effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2445789/),%,51.35,13829,DB00327,Hydromorphone
,2445789,absolute bioavailability,"Hydromorphone has an absolute bioavailability of 51.35 +/- 29.29% and 36.33 +/- 29.60% after peroral and rectal administration, respectively.",Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plasma ratio and clinical effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2445789/),%,36.33,13830,DB00327,Hydromorphone
,26309104,terminal half-life,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,1.56,15188,DB00327,Hydromorphone
,26309104,maximum serum concentration,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),[ng] / [ml],155.6,15189,DB00327,Hydromorphone
,26309104,time to maximum serum concentration,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,3.90,15190,DB00327,Hydromorphone
,26309104,maximum serum concentration,"For hydrocodone, maximum serum concentration determined by naïve pooled modeling was 7.90 ng/mL, and time to maximum serum concentration was 3.47 hours.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),[ng] / [ml],7.90,15191,DB00327,Hydromorphone
,26309104,time to maximum serum concentration,"For hydrocodone, maximum serum concentration determined by naïve pooled modeling was 7.90 ng/mL, and time to maximum serum concentration was 3.47 hours.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,3.47,15192,DB00327,Hydromorphone
,26309104,terminal half-life,"The terminal half-life for hydrocodone was 15.85 hours, but was likely influenced by delayed drug absorption in some dogs and may not have been a robust estimate.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,15.85,15193,DB00327,Hydromorphone
,32228262,clearance,"Mean ± SD clearance and volume of distribution for hydromorphone administered IV were 52.8 ± 13.5 mL/min/kg and 2.39 ± 0.479 L/kg, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (Cavia porcellus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32228262/),[ml] / [kg·min],52.8,17172,DB00327,Hydromorphone
,32228262,volume of distribution,"Mean ± SD clearance and volume of distribution for hydromorphone administered IV were 52.8 ± 13.5 mL/min/kg and 2.39 ± 0.479 L/kg, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (Cavia porcellus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32228262/),[l] / [kg],2.39,17173,DB00327,Hydromorphone
,32228262,Mean residence time,"Mean residence time determined for the IV and IM administration routes was 0.77 ± 0.14 hours and 0.99 ± 0.34 hours, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (Cavia porcellus). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32228262/),h,0.77,17174,DB00327,Hydromorphone
,32228262,Mean residence time,"Mean residence time determined for the IV and IM administration routes was 0.77 ± 0.14 hours and 0.99 ± 0.34 hours, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (Cavia porcellus). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32228262/),h,0.99,17175,DB00327,Hydromorphone
,32228262,maximum observed plasma concentration,The maximum observed plasma concentration following IM administration of hydromorphone was 171.9 ± 29.4 ng/mL.,Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32228262/),[ng] / [ml],171.9,17176,DB00327,Hydromorphone
,32228262,target plasma concentration,Pharmacokinetic data indicated that hydromorphone at a dose of 0.3 mg/kg may be administered IV every 2 to 3 hours or IM every 4 to 5 hours to maintain a target plasma concentration between 2 and 4 ng/mL in guinea pigs.,Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32228262/),[ng] / [ml],2 and 4,17177,DB00327,Hydromorphone
,17523726,Maximum plasma concentrations,"Maximum plasma concentrations were 3.69 and 3.38 mug/L for treatments B and C, respectively.",Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523726/),[μg] / [l],3.69,34350,DB00327,Hydromorphone
,17523726,Maximum plasma concentrations,"Maximum plasma concentrations were 3.69 and 3.38 mug/L for treatments B and C, respectively.",Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523726/),[μg] / [l],3.38,34351,DB00327,Hydromorphone
,17523726,bioavailability,"Mean (% coefficient of variation) bioavailability of intranasal hydromorphone was 54.4% (34.8) and 59.8% (22.1) with and without pretreatment, respectively.",Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523726/),%,54.4,34352,DB00327,Hydromorphone
,17523726,bioavailability,"Mean (% coefficient of variation) bioavailability of intranasal hydromorphone was 54.4% (34.8) and 59.8% (22.1) with and without pretreatment, respectively.",Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523726/),%,59.8,34353,DB00327,Hydromorphone
,18062845,T(max),Median T(max) values were between 12 and 16 h and ranges were similar for all treatments.,Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18062845/),h,12 and 16,34454,DB00327,Hydromorphone
,25807927,tmax,"Following administration of the ER tablet, plasma concentrations of hydromorphone slowly increased with a median tmax of 5.0 h and the Cmax decreased to 37% of the IR tablet, while the AUC0-inf was comparable with that of the IR tablet when administered at the same dose.","Single-dose evaluation of safety, tolerability and pharmacokinetics of newly formulated hydromorphone immediate-release and hydrophilic matrix extended-release tablets in healthy Japanese subjects without co-administration of an opioid antagonist. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25807927/),h,5.0,36948,DB00327,Hydromorphone
,33177323,oral bioavailability,"The maximum concentration of oral hydromorphone was reduced by 37% (ratio to control: 0.63, 90% CI, 0.55-0.72), and oral bioavailability decreased from 33% to 26% (ratio to control: 0.78, 90% CI, 0.67-0.91) in the rifampin phase compared with placebo.",Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33177323/),%,33,38402,DB00327,Hydromorphone
,33177323,oral bioavailability,"The maximum concentration of oral hydromorphone was reduced by 37% (ratio to control: 0.63, 90% CI, 0.55-0.72), and oral bioavailability decreased from 33% to 26% (ratio to control: 0.78, 90% CI, 0.67-0.91) in the rifampin phase compared with placebo.",Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33177323/),%,26,38403,DB00327,Hydromorphone
,17329173,total chromatographic run time,The method had a total chromatographic run time of 4.5 min and linear calibration curves over the concentration range of 10-5000 pg/mL.,Application of a sensitive liquid chromatographic/tandem mass spectrometric method to pharmacokinetic study of nalmefene in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329173/),min,4.5,48170,DB00327,Hydromorphone
,33107746,bioavailability,"After IM administration, mean bioavailability was 97.6%, and mean maximum plasma concentration was 179.1 ng/mL 17 minutes after injection.",Pharmacokinetics of hydromorphone hydrochloride after intramuscular and intravenous administration of a single dose to orange-winged Amazon parrots (Amazona amazonica). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107746/),%,97.6,54242,DB00327,Hydromorphone
,33107746,maximum plasma concentration,"After IM administration, mean bioavailability was 97.6%, and mean maximum plasma concentration was 179.1 ng/mL 17 minutes after injection.",Pharmacokinetics of hydromorphone hydrochloride after intramuscular and intravenous administration of a single dose to orange-winged Amazon parrots (Amazona amazonica). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107746/),[ng] / [ml],179.1,54243,DB00327,Hydromorphone
,33107746,volume of distribution,"Mean volume of distribution and plasma drug clearance were 4.24 L/kg and 64.2 mL/min/kg, respectively, after IV administration.",Pharmacokinetics of hydromorphone hydrochloride after intramuscular and intravenous administration of a single dose to orange-winged Amazon parrots (Amazona amazonica). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107746/),[l] / [kg],4.24,54244,DB00327,Hydromorphone
,33107746,plasma drug clearance,"Mean volume of distribution and plasma drug clearance were 4.24 L/kg and 64.2 mL/min/kg, respectively, after IV administration.",Pharmacokinetics of hydromorphone hydrochloride after intramuscular and intravenous administration of a single dose to orange-winged Amazon parrots (Amazona amazonica). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107746/),[ml] / [kg·min],64.2,54245,DB00327,Hydromorphone
,33107746,elimination half-lives,"Mean elimination half-lives were 1.74 and 1.45 hours after IM and IV administration, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intramuscular and intravenous administration of a single dose to orange-winged Amazon parrots (Amazona amazonica). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107746/),h,1.74,54246,DB00327,Hydromorphone
,33107746,elimination half-lives,"Mean elimination half-lives were 1.74 and 1.45 hours after IM and IV administration, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intramuscular and intravenous administration of a single dose to orange-winged Amazon parrots (Amazona amazonica). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107746/),h,1.45,54247,DB00327,Hydromorphone
,21404039,MRT(0-INF),LE-hydro (MRT(0-INF) = 105.9 h) demonstrated extended-release pharmacokinetics compared to hydro when administered by either i.v. (MRT(0-INF) =1.1 h) or s.c. (MRT(0-INF) =1.3 h) routes.,Pharmacokinetics and behavioral effects of liposomal hydromorphone suitable for perioperative use in rhesus macaques. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21404039/),h,105.9,55735,DB00327,Hydromorphone
,21404039,MRT(0-INF),LE-hydro (MRT(0-INF) = 105.9 h) demonstrated extended-release pharmacokinetics compared to hydro when administered by either i.v. (MRT(0-INF) =1.1 h) or s.c. (MRT(0-INF) =1.3 h) routes.,Pharmacokinetics and behavioral effects of liposomal hydromorphone suitable for perioperative use in rhesus macaques. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21404039/),h,1.1,55736,DB00327,Hydromorphone
,21404039,MRT(0-INF),LE-hydro (MRT(0-INF) = 105.9 h) demonstrated extended-release pharmacokinetics compared to hydro when administered by either i.v. (MRT(0-INF) =1.1 h) or s.c. (MRT(0-INF) =1.3 h) routes.,Pharmacokinetics and behavioral effects of liposomal hydromorphone suitable for perioperative use in rhesus macaques. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21404039/),h,1.3,55737,DB00327,Hydromorphone
,1704089,bioavailability,Plasma hydromorphone concentrations measured at 24 h and 48 h of infusion showed stable steady-state pharmacokinetics; the mean bioavailability from subcutaneous infusion was 78% of that with intravenous infusion.,Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704089/),%,78,57307,DB00327,Hydromorphone
,24866507,fraction of,The fraction of the hydromorphone dose absorbed after IM administration was 0.75.,Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration of a single dose to American kestrels (Falco sparverius). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24866507/),,0,59485,DB00327,Hydromorphone
,24866507,maximum observed plasma concentration,The maximum observed plasma concentration was 112.1 ng/mL (5 minutes after administration).,Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration of a single dose to American kestrels (Falco sparverius). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24866507/),[ng] / [ml],112.1,59486,DB00327,Hydromorphone
,24866507,terminal half-life,"The terminal half-life was 1.25 and 1.26 hours after IV and IM administration, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration of a single dose to American kestrels (Falco sparverius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24866507/),h,1.25,59487,DB00327,Hydromorphone
,24866507,terminal half-life,"The terminal half-life was 1.25 and 1.26 hours after IV and IM administration, respectively.",Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration of a single dose to American kestrels (Falco sparverius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24866507/),h,1.26,59488,DB00327,Hydromorphone
,12357147,absolute bioavailability,"The mean absolute bioavailability for the 8-mg OROS formulation was significantly larger ( = 0.025) than for the 8-mg IR formulation: 0.24 (SD 0.059) versus 0.19 (SD 0.054), respectively.",Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357147/),,0,62317,DB00327,Hydromorphone
,12357147,absolute bioavailability,"The mean absolute bioavailability for the 8-mg OROS formulation was significantly larger ( = 0.025) than for the 8-mg IR formulation: 0.24 (SD 0.059) versus 0.19 (SD 0.054), respectively.",Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357147/),,0.24,62318,DB00327,Hydromorphone
,12357147,absolute bioavailability,"The mean absolute bioavailability for the 8-mg OROS formulation was significantly larger ( = 0.025) than for the 8-mg IR formulation: 0.24 (SD 0.059) versus 0.19 (SD 0.054), respectively.",Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357147/),,0.19,62319,DB00327,Hydromorphone
,30827804,half-life,"The half-life of hydromorphone administered at 0.5 and 1.0 mg kg-1 was 2.54 and 3.05 hours in bearded dragons and 2.67 and 2.01 hours in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),h,2.54,64365,DB00327,Hydromorphone
,30827804,half-life,"The half-life of hydromorphone administered at 0.5 and 1.0 mg kg-1 was 2.54 and 3.05 hours in bearded dragons and 2.67 and 2.01 hours in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),h,3.05,64366,DB00327,Hydromorphone
,30827804,half-life,"The half-life of hydromorphone administered at 0.5 and 1.0 mg kg-1 was 2.54 and 3.05 hours in bearded dragons and 2.67 and 2.01 hours in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),h,2.67,64367,DB00327,Hydromorphone
,30827804,half-life,"The half-life of hydromorphone administered at 0.5 and 1.0 mg kg-1 was 2.54 and 3.05 hours in bearded dragons and 2.67 and 2.01 hours in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),h,2.01,64368,DB00327,Hydromorphone
,30827804,maximum plasma concentrations,"The maximum plasma concentrations for 0.5 and 1.0 mg kg-1 were 142 and 369 ng mL-1 in bearded dragons and 1610 and 5142 ng mL-1 in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),[ng] / [ml],142,64369,DB00327,Hydromorphone
,30827804,maximum plasma concentrations,"The maximum plasma concentrations for 0.5 and 1.0 mg kg-1 were 142 and 369 ng mL-1 in bearded dragons and 1610 and 5142 ng mL-1 in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),[ng] / [ml],369,64370,DB00327,Hydromorphone
,30827804,maximum plasma concentrations,"The maximum plasma concentrations for 0.5 and 1.0 mg kg-1 were 142 and 369 ng mL-1 in bearded dragons and 1610 and 5142 ng mL-1 in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),[ng] / [ml],1610,64371,DB00327,Hydromorphone
,30827804,maximum plasma concentrations,"The maximum plasma concentrations for 0.5 and 1.0 mg kg-1 were 142 and 369 ng mL-1 in bearded dragons and 1610 and 5142 ng mL-1 in red-eared sliders, respectively.",Pharmacokinetics of subcutaneously administered hydromorphone in bearded dragons (Pogona vitticeps) and red-eared slider turtles (Trachemys scripta elegans). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30827804/),[ng] / [ml],5142,64372,DB00327,Hydromorphone
,26350273,Cmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],16.8,65144,DB00327,Hydromorphone
,26350273,Cmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],15.9,65145,DB00327,Hydromorphone
,26350273,t½,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],16.8,65146,DB00327,Hydromorphone
,26350273,t½,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],15.9,65147,DB00327,Hydromorphone
,26350273,t½,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,8.5,65148,DB00327,Hydromorphone
,26350273,Tmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,8.4,65149,DB00327,Hydromorphone
,26350273,Tmax,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,18.0,65150,DB00327,Hydromorphone
,26350273,AUC0-t,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],342.9,65151,DB00327,Hydromorphone
,26350273,AUC0-∞,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],325.3,65152,DB00327,Hydromorphone
,26350273,AUC0-∞,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],346.3,65153,DB00327,Hydromorphone
,26350273,AUC0-∞,"Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs 8.4 hours, and 18.0 vs 18.0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342.9 vs 325.3 ng · h/mL and 346.3 vs 328.5 ng · h/mL).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],328.5,65154,DB00327,Hydromorphone
,26350273,AUC0-t,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],0.64,65155,DB00327,Hydromorphone
,26350273,AUC0-t,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],3.8,65156,DB00327,Hydromorphone
,26350273,Cmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[h·ng] / [ml],3.8,65157,DB00327,Hydromorphone
,26350273,Cmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],0.06,65158,DB00327,Hydromorphone
,26350273,Cmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),[ng] / [ml],0.19,65159,DB00327,Hydromorphone
,26350273,Tmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,18.0,65160,DB00327,Hydromorphone
,26350273,Tmax,"Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0.64 vs 3.8 ng · h/mL and 0.06 vs 0.19 ng/mL), whereas Tmax values remained similar (18.0 vs 16.1 hours, respectively).","Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350273/),h,16.1,65161,DB00327,Hydromorphone
,23166450,AUC(0-24),"Dose-normalized to 16 mg, mean pharmacokinetic parameter values were: AUC(0-24), 41.1 ng · h/mL; C(max), 2.6 ng/mL; C(min), 1.1 ng/mL; C(avg), 1.7 ng/mL; and the degree of fluctuation was 99.6%.",Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23166450/),[h·ng] / [ml],41.1,66022,DB00327,Hydromorphone
,23166450,C(max),"Dose-normalized to 16 mg, mean pharmacokinetic parameter values were: AUC(0-24), 41.1 ng · h/mL; C(max), 2.6 ng/mL; C(min), 1.1 ng/mL; C(avg), 1.7 ng/mL; and the degree of fluctuation was 99.6%.",Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23166450/),[ng] / [ml],2.6,66023,DB00327,Hydromorphone
,23166450,C(min),"Dose-normalized to 16 mg, mean pharmacokinetic parameter values were: AUC(0-24), 41.1 ng · h/mL; C(max), 2.6 ng/mL; C(min), 1.1 ng/mL; C(avg), 1.7 ng/mL; and the degree of fluctuation was 99.6%.",Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23166450/),[ng] / [ml],1.1,66024,DB00327,Hydromorphone
,23166450,C(avg),"Dose-normalized to 16 mg, mean pharmacokinetic parameter values were: AUC(0-24), 41.1 ng · h/mL; C(max), 2.6 ng/mL; C(min), 1.1 ng/mL; C(avg), 1.7 ng/mL; and the degree of fluctuation was 99.6%.",Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23166450/),[ng] / [ml],1.7,66025,DB00327,Hydromorphone
,29996718,rate,Median fentanyl rate of 100 µg/h was transitioned to 1 mg/h of hydromorphone.,Transition From Continuous Infusion Fentanyl to Hydromorphone in Critically Ill Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29996718/),[μg] / [h],100,84321,DB00327,Hydromorphone
,1713663,maximum blood morphine concentration,A maximum blood morphine concentration of 60 +/- 25 ng/ml (mean +/- S.D.) was obtained at 11 +/- 6 min (mean +/- S.D.).,CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713663/),[ng] / [ml],60,88846,DB00327,Hydromorphone
,1713663,peak,The blood hydromorphone peak of 14 +/- 13 ng/ml (mean +/- S.D.) occurred 8 +/- 6 min (mean +/- S.D.).,CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713663/),[ng] / [ml],14,88847,DB00327,Hydromorphone
,1713663,peak CSF opioid concentrations,The mean peak CSF opioid concentrations of 1581 ng/ml for morphine and 309 ng/ml for hydromorphone occurred 60 min after epidural administration.,CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713663/),[ng] / [ml],1581,88848,DB00327,Hydromorphone
,1713663,peak CSF opioid concentrations,The mean peak CSF opioid concentrations of 1581 ng/ml for morphine and 309 ng/ml for hydromorphone occurred 60 min after epidural administration.,CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713663/),[ng] / [ml],309,88849,DB00327,Hydromorphone
,19192761,pain scores,Mean MPQ pain scores decreased from 39.8 (18.2) to 12.3 (16.2) on dialysis and from 35.0 (18.5) to 15.5 (13.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,39.8,104196,DB00327,Hydromorphone
,19192761,pain scores,Mean MPQ pain scores decreased from 39.8 (18.2) to 12.3 (16.2) on dialysis and from 35.0 (18.5) to 15.5 (13.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,12.3,104197,DB00327,Hydromorphone
,19192761,pain scores,Mean MPQ pain scores decreased from 39.8 (18.2) to 12.3 (16.2) on dialysis and from 35.0 (18.5) to 15.5 (13.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,35.0,104198,DB00327,Hydromorphone
,19192761,pain scores,Mean MPQ pain scores decreased from 39.8 (18.2) to 12.3 (16.2) on dialysis and from 35.0 (18.5) to 15.5 (13.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,15.5,104199,DB00327,Hydromorphone
,19192761,VAS pain scores,Mean VAS pain scores decreased from 7.5 (2.5) to 3.0 (1.5) on dialysis and from 5.9 (3.2) to 4.4 (1.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,7.5,104200,DB00327,Hydromorphone
,19192761,VAS pain scores,Mean VAS pain scores decreased from 7.5 (2.5) to 3.0 (1.5) on dialysis and from 5.9 (3.2) to 4.4 (1.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,3.0,104201,DB00327,Hydromorphone
,19192761,VAS pain scores,Mean VAS pain scores decreased from 7.5 (2.5) to 3.0 (1.5) on dialysis and from 5.9 (3.2) to 4.4 (1.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,5.9,104202,DB00327,Hydromorphone
,19192761,VAS pain scores,Mean VAS pain scores decreased from 7.5 (2.5) to 3.0 (1.5) on dialysis and from 5.9 (3.2) to 4.4 (1.6) between dialysis treatments.,Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192761/),,4.4,104203,DB00327,Hydromorphone
,30290794,ED50,The ED50 of hydromorphone in our population was 10.9 μg (95% confidence interval 5.6-16.2 μg).,Determination of ED50 and time to effectiveness for intrathecal hydromorphone in laboring patients using Dixon's up-and-down sequential allocation method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30290794/),μg,10.9,105843,DB00327,Hydromorphone
,30290794,time to pain relief,"Amongst patients for whom the dose was effective, the median time to pain relief was 24 min.",Determination of ED50 and time to effectiveness for intrathecal hydromorphone in laboring patients using Dixon's up-and-down sequential allocation method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30290794/),min,24,105844,DB00327,Hydromorphone
,31353195,Clearance (CL,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg·min],33.2,110008,DB00327,Hydromorphone
,31353195,Clearance (CL,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg·min],61.3,110009,DB00327,Hydromorphone
,31353195,maximum concentration,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ng] / [ml],33.6,110010,DB00327,Hydromorphone
,31353195,maximum concentration,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ng] / [ml],20.0,110011,DB00327,Hydromorphone
,31353195,apparent volume of the rapid peripheral compartment,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],436,110012,DB00327,Hydromorphone
,31353195,apparent volume of the rapid peripheral compartment,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],925,110013,DB00327,Hydromorphone
,31353195,apparent volume at steady state,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],4064,110014,DB00327,Hydromorphone
,31353195,apparent volume at steady state,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],7195,110015,DB00327,Hydromorphone
,1711119,limit of quant,The limit of quantitation was 0.3 ng/mL of plasma for morphine and 50 pg/mL of plasma for hydromorphone.,Sensitive and specific radioimmunoassays for opiates using commercially available materials. I: Methods for the determinations of morphine and hydromorphone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711119/),[ng] / [ml],0.3,111133,DB00327,Hydromorphone
,1711119,limit of quant,The limit of quantitation was 0.3 ng/mL of plasma for morphine and 50 pg/mL of plasma for hydromorphone.,Sensitive and specific radioimmunoassays for opiates using commercially available materials. I: Methods for the determinations of morphine and hydromorphone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711119/),p,50,111134,DB00327,Hydromorphone
,6165742,half-life of elimination,"In a relatively small pilot study, the half-life of elimination of hydromorphone in six subjects was 2.64 +/- 0.88 hours and the drug had a high volume of distribution, 1.22 l./kg.",Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6165742/),h,2.64,111760,DB00327,Hydromorphone
,6165742,volume of distribution,"In a relatively small pilot study, the half-life of elimination of hydromorphone in six subjects was 2.64 +/- 0.88 hours and the drug had a high volume of distribution, 1.22 l./kg.",Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6165742/),[l] / [kg],1.22,111761,DB00327,Hydromorphone
,25015174,effective concentration at 50 % of maximum (EC50),A saturable maximum effect (E max) model with 0.67 ng/mL effective concentration at 50 % of maximum (EC50) and 91 % E max best described µORO versus buprenorphine plasma concentrations.,"A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015174/),[ng] / [ml],0.67,129419,DB00327,Hydromorphone
,25015174,E max,A saturable maximum effect (E max) model with 0.67 ng/mL effective concentration at 50 % of maximum (EC50) and 91 % E max best described µORO versus buprenorphine plasma concentrations.,"A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25015174/),%,91,129420,DB00327,Hydromorphone
,23098635,CMAX,The mean hydrocodone CMAX was 11.73 ng/mL at 0.74 h with a terminal half-life of 1.60 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),[ng] / [ml],11.73,129788,DB00327,Hydromorphone
,23098635,terminal half-life,The mean hydrocodone CMAX was 11.73 ng/mL at 0.74 h with a terminal half-life of 1.60 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),h,1.60,129789,DB00327,Hydromorphone
,23098635,CMAX,The mean hydromorphone CMAX was 5.2 ng/mL at 1.37 h with a terminal half-life of 3.07 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),[ng] / [ml],5.2,129790,DB00327,Hydromorphone
,23098635,terminal half-life,The mean hydromorphone CMAX was 5.2 ng/mL at 1.37 h with a terminal half-life of 3.07 h.,Pharmacokinetics of hydrocodone and hydromorphone after oral hydrocodone in healthy Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23098635/),h,3.07,129791,DB00327,Hydromorphone
,32409257,HR,"HR and SAP were 59 ± 17 beats minute-1 and 230 ± 27 mmHg, respectively, in treatment H0.05 at 5 minutes after administration.",Pharmacokinetics and pharmacodynamics of hydromorphone hydrochloride in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32409257/),[beats] / [min],59,148696,DB00327,Hydromorphone
,32409257,SAP,"HR and SAP were 59 ± 17 beats minute-1 and 230 ± 27 mmHg, respectively, in treatment H0.05 at 5 minutes after administration.",Pharmacokinetics and pharmacodynamics of hydromorphone hydrochloride in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32409257/),mmhg,230,148697,DB00327,Hydromorphone
,32409257,volume of distribution at steady state,"For hydromorphone, mean ± standard deviation for volume of distribution at steady state, total systemic clearance and area under the curve until the last measured concentration were 1.00 ± 0.29 L kg-1, 106 ± 21 mL minute-1 kg-1 and 8.0 ± 1.5 ng hour mL-1, respectively.",Pharmacokinetics and pharmacodynamics of hydromorphone hydrochloride in healthy horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32409257/),[l] / [kg],1.00,148698,DB00327,Hydromorphone
,32409257,total systemic clearance,"For hydromorphone, mean ± standard deviation for volume of distribution at steady state, total systemic clearance and area under the curve until the last measured concentration were 1.00 ± 0.29 L kg-1, 106 ± 21 mL minute-1 kg-1 and 8.0 ± 1.5 ng hour mL-1, respectively.",Pharmacokinetics and pharmacodynamics of hydromorphone hydrochloride in healthy horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32409257/),[ml] / [kg·min],106,148699,DB00327,Hydromorphone
,32409257,area under the curve until,"For hydromorphone, mean ± standard deviation for volume of distribution at steady state, total systemic clearance and area under the curve until the last measured concentration were 1.00 ± 0.29 L kg-1, 106 ± 21 mL minute-1 kg-1 and 8.0 ± 1.5 ng hour mL-1, respectively.",Pharmacokinetics and pharmacodynamics of hydromorphone hydrochloride in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32409257/),[h·ng] / [ml],8.0,148700,DB00327,Hydromorphone
,8917240,plasma hydromorphone,"The mean plasma hydromorphone concentration was 4.7 ng/ml (range, 1.9 to 8.9 ng/ml), and the mean clearance was 51.7 ml/min per kilogram of body weight (range, 28.6 to 98.2 ml/min per kilogram).",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),[ng] / [ml],4.7,148893,DB00327,Hydromorphone
,8917240,concentration,"The mean plasma hydromorphone concentration was 4.7 ng/ml (range, 1.9 to 8.9 ng/ml), and the mean clearance was 51.7 ml/min per kilogram of body weight (range, 28.6 to 98.2 ml/min per kilogram).",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),[ng] / [ml],4.7,148894,DB00327,Hydromorphone
,8917240,clearance,"The mean plasma hydromorphone concentration was 4.7 ng/ml (range, 1.9 to 8.9 ng/ml), and the mean clearance was 51.7 ml/min per kilogram of body weight (range, 28.6 to 98.2 ml/min per kilogram).",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),[ml] / [kg·min],51.7,148895,DB00327,Hydromorphone
,8917240,concentrations,"The mean plasma morphine, morphine-6-glucuronide, and morphine-3-glucuronide concentrations were 40.0 ng/ml (range, 15 to 62.5), 168.2 ng/ml (range, 54.4 to 231.9), and 391.0 ng/ml (range, 149.4 to 921.7), respectively.",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),[ng] / [ml],168.2,148896,DB00327,Hydromorphone
,8917240,concentrations,"The mean plasma morphine, morphine-6-glucuronide, and morphine-3-glucuronide concentrations were 40.0 ng/ml (range, 15 to 62.5), 168.2 ng/ml (range, 54.4 to 231.9), and 391.0 ng/ml (range, 149.4 to 921.7), respectively.",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),[ng] / [ml],391.0,148897,DB00327,Hydromorphone
,8917240,clearance,"The mean morphine clearance was 34.3 ml/min per kilogram of body weight (range, 19.3 to 58.3).",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),[ml] / [kg·min],34.3,148898,DB00327,Hydromorphone
,8917240,molar ratios,"The mean molar ratios of morphine-6-glucuronide/morphine, morphine-3-glucoronide/morphine, and morphine-3-glucuronide/morphine-6-glucuronide were 2.48 (range, 1.4 to 3.3), 5.82 (range, 3.4 to 9.1), and 2.46 (range, 1.1 to 3.3), respectively.",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),,2.48,148899,DB00327,Hydromorphone
,8917240,molar ratios,"The mean molar ratios of morphine-6-glucuronide/morphine, morphine-3-glucoronide/morphine, and morphine-3-glucuronide/morphine-6-glucuronide were 2.48 (range, 1.4 to 3.3), 5.82 (range, 3.4 to 9.1), and 2.46 (range, 1.1 to 3.3), respectively.",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),,5.82,148900,DB00327,Hydromorphone
,8917240,molar ratios,"The mean molar ratios of morphine-6-glucuronide/morphine, morphine-3-glucoronide/morphine, and morphine-3-glucuronide/morphine-6-glucuronide were 2.48 (range, 1.4 to 3.3), 5.82 (range, 3.4 to 9.1), and 2.46 (range, 1.1 to 3.3), respectively.",Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917240/),,2.46,148901,DB00327,Hydromorphone
,12818953,bioavailabilities,"Mean hydromorphone bioavailabilities and percent coefficient of variation of 52.4% (22.7) and 57.5% (18.6) were seen after the 1.0- and 2.0-mg IN doses, respectively.",Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818953/),%,52.4,159413,DB00327,Hydromorphone
,12818953,percent coefficient,"Mean hydromorphone bioavailabilities and percent coefficient of variation of 52.4% (22.7) and 57.5% (18.6) were seen after the 1.0- and 2.0-mg IN doses, respectively.",Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818953/),%,52.4,159414,DB00327,Hydromorphone
,12818953,percent coefficient,"Mean hydromorphone bioavailabilities and percent coefficient of variation of 52.4% (22.7) and 57.5% (18.6) were seen after the 1.0- and 2.0-mg IN doses, respectively.",Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818953/),%,57.5,159415,DB00327,Hydromorphone
,12818953,times to maximum concentration,Median times to maximum concentration were 20 and 25 min for IN doses.,Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818953/),min,20,159416,DB00327,Hydromorphone
,12818953,times to maximum concentration,Median times to maximum concentration were 20 and 25 min for IN doses.,Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12818953/),min,25,159417,DB00327,Hydromorphone
,18638294,elimination half-life,"Mean elimination half-life was 80 +/- 52.7 and 57.7 +/- 30.4 min for the high and low dose, respectively.",Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638294/),min,80,159873,DB00327,Hydromorphone
,18638294,elimination half-life,"Mean elimination half-life was 80 +/- 52.7 and 57.7 +/- 30.4 min for the high and low dose, respectively.",Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638294/),min,57.7,159874,DB00327,Hydromorphone
,18638294,apparent mean volumes of distribution at steady-state,"The apparent mean volumes of distribution at steady-state were 7.2 +/- 3 and 4.5 +/- 2.4 L/kg, while the clearance was 74.7 +/- 19 and 68.1 +/- 20 mL/kg/min for the high and low doses, respectively.",Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638294/),[l] / [kg],7.2,159875,DB00327,Hydromorphone
,18638294,apparent mean volumes of distribution at steady-state,"The apparent mean volumes of distribution at steady-state were 7.2 +/- 3 and 4.5 +/- 2.4 L/kg, while the clearance was 74.7 +/- 19 and 68.1 +/- 20 mL/kg/min for the high and low doses, respectively.",Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638294/),[l] / [kg],4.5,159876,DB00327,Hydromorphone
,18638294,clearance,"The apparent mean volumes of distribution at steady-state were 7.2 +/- 3 and 4.5 +/- 2.4 L/kg, while the clearance was 74.7 +/- 19 and 68.1 +/- 20 mL/kg/min for the high and low doses, respectively.",Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638294/),[ml] / [kg·min],74.7,159877,DB00327,Hydromorphone
,18638294,clearance,"The apparent mean volumes of distribution at steady-state were 7.2 +/- 3 and 4.5 +/- 2.4 L/kg, while the clearance was 74.7 +/- 19 and 68.1 +/- 20 mL/kg/min for the high and low doses, respectively.",Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638294/),[ml] / [kg·min],68.1,159878,DB00327,Hydromorphone
,14740785,absolute bioavailability,"Mean (% coefficient of variation) absolute bioavailability of intranasal hydromorphone was 51.9% (28.2) and 46.9% (30.3) in patients with allergic rhinitis with and without treatment with fluticasone propionate, respectively.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),%,51.9,163996,DB00327,Hydromorphone
,14740785,absolute bioavailability,"Mean (% coefficient of variation) absolute bioavailability of intranasal hydromorphone was 51.9% (28.2) and 46.9% (30.3) in patients with allergic rhinitis with and without treatment with fluticasone propionate, respectively.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),%,46.9,163997,DB00327,Hydromorphone
,14740785,maximum concentration (Cmax),"Mean maximum concentration (Cmax) values were 3.02 and 3.56 ng/ml, respectively.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),[ng] / [ml],3.02,163998,DB00327,Hydromorphone
,14740785,maximum concentration (Cmax),"Mean maximum concentration (Cmax) values were 3.02 and 3.56 ng/ml, respectively.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),[ng] / [ml],3.56,163999,DB00327,Hydromorphone
,14740785,Bioavailability,Bioavailability values for both intranasal treatments were lower than those in healthy volunteers (57%).,Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),%,57,164000,DB00327,Hydromorphone
,14740785,time to Cmax (Tmax),"Median time to Cmax (Tmax) values were significantly different (p=0.02) for treatments B and C (15 and 30 min, respectively) using rank-transformed Tmax for ANOVA.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),min,15,164001,DB00327,Hydromorphone
,14740785,time to Cmax (Tmax),"Median time to Cmax (Tmax) values were significantly different (p=0.02) for treatments B and C (15 and 30 min, respectively) using rank-transformed Tmax for ANOVA.",Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14740785/),min,30,164002,DB00327,Hydromorphone
,2470073,steady-state plasma concentration,The transdermal permeation of hydromorphone was also evaluated for 24 hr and a steady-state plasma concentration (0.135 micrograms/ml) was achieved during the 6- to 24-hr periods following the application of a transdermal patch on the inner pinna of the rabbit's ear.,Pharmacokinetics and bioavailability of hydromorphone: effect of various routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2470073/),[μg] / [ml],0.135,165306,DB00327,Hydromorphone
>,32486995,bioavailability,For drugs with a high bioavailability (> 70 %) only the impaired hepatic clearance has to be considered.,[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167613,DB00327,Hydromorphone
>,32486995,bioavailability,"Buprenorphine, fentanyl, hydromorphone, morphine, naloxone und tapentadol are drugs with a high first-pass effect, while the bioavailability of methadone, oxycodone and tramadol is > 70 %.",[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167614,DB00327,Hydromorphone
,18282253,serum half-life,"The serum half-life, clearance, and volume of distribution after IV hydromorphone at 0.1 mg kg(-1) were 0.57 hours (geometric mean), 106.28 mL minute(-1) kg(-1), and 5.35 L kg(-1), and at 0.5 mg kg(-1) were 1.00 hour, 60.30 mL minute(-1) kg(-1), and 5.23 L kg(-1), respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),h,0.57,169946,DB00327,Hydromorphone
,18282253,clearance,"The serum half-life, clearance, and volume of distribution after IV hydromorphone at 0.1 mg kg(-1) were 0.57 hours (geometric mean), 106.28 mL minute(-1) kg(-1), and 5.35 L kg(-1), and at 0.5 mg kg(-1) were 1.00 hour, 60.30 mL minute(-1) kg(-1), and 5.23 L kg(-1), respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),[ml] / [kg·minute],106.28,169947,DB00327,Hydromorphone
,18282253,clearance,"The serum half-life, clearance, and volume of distribution after IV hydromorphone at 0.1 mg kg(-1) were 0.57 hours (geometric mean), 106.28 mL minute(-1) kg(-1), and 5.35 L kg(-1), and at 0.5 mg kg(-1) were 1.00 hour, 60.30 mL minute(-1) kg(-1), and 5.23 L kg(-1), respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),[ml] / [kg·minute],60.30,169948,DB00327,Hydromorphone
,18282253,volume of distribution,"The serum half-life, clearance, and volume of distribution after IV hydromorphone at 0.1 mg kg(-1) were 0.57 hours (geometric mean), 106.28 mL minute(-1) kg(-1), and 5.35 L kg(-1), and at 0.5 mg kg(-1) were 1.00 hour, 60.30 mL minute(-1) kg(-1), and 5.23 L kg(-1), respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),[l] / [kg],5.35,169949,DB00327,Hydromorphone
,18282253,volume of distribution,"The serum half-life, clearance, and volume of distribution after IV hydromorphone at 0.1 mg kg(-1) were 0.57 hours (geometric mean), 106.28 mL minute(-1) kg(-1), and 5.35 L kg(-1), and at 0.5 mg kg(-1) were 1.00 hour, 60.30 mL minute(-1) kg(-1), and 5.23 L kg(-1), respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),[l] / [kg],5.23,169950,DB00327,Hydromorphone
,18282253,serum half-life,"The serum half-life after SC hydromorphone at 0.1 mg kg(-1) and 0.5 mg kg(-1) was 0.66 hours and 1.11 hours, respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),h,0.66,169951,DB00327,Hydromorphone
,18282253,serum half-life,"The serum half-life after SC hydromorphone at 0.1 mg kg(-1) and 0.5 mg kg(-1) was 0.66 hours and 1.11 hours, respectively.",Pharmacokinetics of hydromorphone hydrochloride in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282253/),h,1.11,169952,DB00327,Hydromorphone
,1704690,detection limit,Concentrations of hydromorphone in plasma from serial blood samples were measured by a high-performance liquid chromatography method specific for hydromorphone with a detection limit of 0.1 ng/mL.,Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),[ng] / [ml],0.1,183043,DB00327,Hydromorphone
,1704690,distribution,"Averaged across doses, the distribution and terminal elimination half-lives were 1.27 min (t1/2 pi), 14.7 min (t1/2 alpha), and 184 min (t1/2 beta), respectively.",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),min,1.27,183044,DB00327,Hydromorphone
,1704690,t1/2 pi,"Averaged across doses, the distribution and terminal elimination half-lives were 1.27 min (t1/2 pi), 14.7 min (t1/2 alpha), and 184 min (t1/2 beta), respectively.",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),min,1.27,183045,DB00327,Hydromorphone
,1704690,t1/2 alpha,"Averaged across doses, the distribution and terminal elimination half-lives were 1.27 min (t1/2 pi), 14.7 min (t1/2 alpha), and 184 min (t1/2 beta), respectively.",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),min,14.7,183046,DB00327,Hydromorphone
,1704690,t1/2 beta,"Averaged across doses, the distribution and terminal elimination half-lives were 1.27 min (t1/2 pi), 14.7 min (t1/2 alpha), and 184 min (t1/2 beta), respectively.",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),min,184,183047,DB00327,Hydromorphone
,1704690,systemic clearance,"Average values for systemic clearance, initial dilution volume, and steady-state volume of distribution were 1.66 L/min (Cl), 24.4 L (Vc), and 295 L (Vdss).",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),[l] / [min],1.66,183048,DB00327,Hydromorphone
,1704690,Cl,"Average values for systemic clearance, initial dilution volume, and steady-state volume of distribution were 1.66 L/min (Cl), 24.4 L (Vc), and 295 L (Vdss).",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),[l] / [min],1.66,183049,DB00327,Hydromorphone
,1704690,Vc,"Average values for systemic clearance, initial dilution volume, and steady-state volume of distribution were 1.66 L/min (Cl), 24.4 L (Vc), and 295 L (Vdss).",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),l,24.4,183050,DB00327,Hydromorphone
,1704690,Vdss,"Average values for systemic clearance, initial dilution volume, and steady-state volume of distribution were 1.66 L/min (Cl), 24.4 L (Vc), and 295 L (Vdss).",Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1704690/),l,295,183051,DB00327,Hydromorphone
,7538514,AUC0-12,"Controlled-release hydromorphone demonstrated equivalent bioavailability and acceptable CR characteristics, when compared with IR hydromorphone (CR vs. IR: AUC0-12 123.10 +/- 20.38 vs. 118.98 +/- 20.92 ng.hr.mL-1, P = NS, Cmax 17.76 +/- 3.07 vs. 19.70 +/- 4.04 ng.",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),[h·ng] / [ml],123.10,184924,DB00327,Hydromorphone
,7538514,AUC0-12,"Controlled-release hydromorphone demonstrated equivalent bioavailability and acceptable CR characteristics, when compared with IR hydromorphone (CR vs. IR: AUC0-12 123.10 +/- 20.38 vs. 118.98 +/- 20.92 ng.hr.mL-1, P = NS, Cmax 17.76 +/- 3.07 vs. 19.70 +/- 4.04 ng.",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),[h·ng] / [ml],118.98,184925,DB00327,Hydromorphone
,7538514,Cmax,"Controlled-release hydromorphone demonstrated equivalent bioavailability and acceptable CR characteristics, when compared with IR hydromorphone (CR vs. IR: AUC0-12 123.10 +/- 20.38 vs. 118.98 +/- 20.92 ng.hr.mL-1, P = NS, Cmax 17.76 +/- 3.07 vs. 19.70 +/- 4.04 ng.",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),ng,17.76,184926,DB00327,Hydromorphone
,7538514,Cmax,"Controlled-release hydromorphone demonstrated equivalent bioavailability and acceptable CR characteristics, when compared with IR hydromorphone (CR vs. IR: AUC0-12 123.10 +/- 20.38 vs. 118.98 +/- 20.92 ng.hr.mL-1, P = NS, Cmax 17.76 +/- 3.07 vs. 19.70 +/- 4.04 ng.",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),ng,19.70,184927,DB00327,Hydromorphone
,7538514,Cmin,"mL-1, P = NS, Cmin 6.04 +/- 1.01 vs. 5.28 +/- 1.000 ng.",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),ng,6.04,184928,DB00327,Hydromorphone
,7538514,Cmin,"mL-1, P = NS, Cmin 6.04 +/- 1.01 vs. 5.28 +/- 1.000 ng.",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),ng,5.28,184929,DB00327,Hydromorphone
,7538514,Tmax,"mL-1, P = NS, and Tmax 4.78 +/- 0.78 vs. 1.47 +/- 0.22 hr, P = 0.0008).",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),h,4.78,184930,DB00327,Hydromorphone
,7538514,Tmax,"mL-1, P = NS, and Tmax 4.78 +/- 0.78 vs. 1.47 +/- 0.22 hr, P = 0.0008).",Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),h,1.47,184931,DB00327,Hydromorphone
,7538514,steady-state molar ratio,The steady-state molar ratio of H3G to hydromorphone was 27:1.,Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7538514/),,27:1,184932,DB00327,Hydromorphone
,15502034,peak plasma concentrations,"After 7 intranasal doses of 1 and 2 mg (once every 6 h), mean +/- sd peak plasma concentrations of 2.8 +/- 0.7 ng/mL and 5.3 +/- 2.3 ng/mL, respectively, were observed.",A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502034/),[ng] / [ml],2.8,188882,DB00327,Hydromorphone
,15502034,peak plasma concentrations,"After 7 intranasal doses of 1 and 2 mg (once every 6 h), mean +/- sd peak plasma concentrations of 2.8 +/- 0.7 ng/mL and 5.3 +/- 2.3 ng/mL, respectively, were observed.",A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502034/),[ng] / [ml],5.3,188883,DB00327,Hydromorphone
,15502034,time to peak concentration,The median time to peak concentration was 20 min for both single and multiple doses.,A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502034/),min,20,188884,DB00327,Hydromorphone
,19000260,half-life,"Serum concentrations of hydromorphone decreased rapidly after IV administration of the DPPC-C formulation (half-life = 0.52 h, volume of distribution = 12.47 L/kg, serum clearance = 128.97 mL/min/kg).",Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),h,0.52,190088,DB00327,Hydromorphone
,19000260,volume of distribution,"Serum concentrations of hydromorphone decreased rapidly after IV administration of the DPPC-C formulation (half-life = 0.52 h, volume of distribution = 12.47 L/kg, serum clearance = 128.97 mL/min/kg).",Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),[l] / [kg],12.47,190089,DB00327,Hydromorphone
,19000260,serum clearance,"Serum concentrations of hydromorphone decreased rapidly after IV administration of the DPPC-C formulation (half-life = 0.52 h, volume of distribution = 12.47 L/kg, serum clearance = 128.97 mL/min/kg).",Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),[ml] / [kg·min],128.97,190090,DB00327,Hydromorphone
,19000260,half-life,"The half-life of hydromorphone after SC administration of DPPC-C formulation at 1.0, 2.0, and 3.0 mg/kg was 5.22, 31.48, and 24.05 h, respectively.",Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),h,5.22,190091,DB00327,Hydromorphone
,19000260,half-life,"The half-life of hydromorphone after SC administration of DPPC-C formulation at 1.0, 2.0, and 3.0 mg/kg was 5.22, 31.48, and 24.05 h, respectively.",Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),h,31.48,190092,DB00327,Hydromorphone
,19000260,half-life,"The half-life of hydromorphone after SC administration of DPPC-C formulation at 1.0, 2.0, and 3.0 mg/kg was 5.22, 31.48, and 24.05 h, respectively.",Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),h,24.05,190093,DB00327,Hydromorphone
,19000260,maximum serum concentration normalized for dose (C(MAX)/D),The maximum serum concentration normalized for dose (C(MAX)/D) ranged between 19.41-24.96 ng/mL occurring at 0.18-0.27 h.,Pharmacokinetics of a controlled-release liposome-encapsulated hydromorphone administered to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000260/),[ng] / [ml],19.41-24.96,190094,DB00327,Hydromorphone
,25653563,area under the plasma concentration versus time curve from time of dosing to time of last detectable concentration (AUC0-t,"Exposure to hydrocodone after HC-ER 20 mg was similar in the fed and fasted states, as assessed by area under the plasma concentration versus time curve from time of dosing to time of last detectable concentration (AUC0-t; 316.14 versus 311.94 ng · h/mL); relative bioavailability (Frel) was 101.74%.","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[h·ng] / [ml],316.14,200806,DB00327,Hydromorphone
,25653563,area under the plasma concentration versus time curve from time of dosing to time of last detectable concentration (AUC0-t,"Exposure to hydrocodone after HC-ER 20 mg was similar in the fed and fasted states, as assessed by area under the plasma concentration versus time curve from time of dosing to time of last detectable concentration (AUC0-t; 316.14 versus 311.94 ng · h/mL); relative bioavailability (Frel) was 101.74%.","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[h·ng] / [ml],311.94,200807,DB00327,Hydromorphone
,25653563,relative bioavailability (Frel),"Exposure to hydrocodone after HC-ER 20 mg was similar in the fed and fasted states, as assessed by area under the plasma concentration versus time curve from time of dosing to time of last detectable concentration (AUC0-t; 316.14 versus 311.94 ng · h/mL); relative bioavailability (Frel) was 101.74%.","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),%,101.74,200808,DB00327,Hydromorphone
,25653563,maximum plasma concentration (Cmax,Differences (fed versus fasted) in hydrocodone mean maximum plasma concentration (Cmax; 28.86 versus 22.74 ng/mL) and median time to Cmax (tmax; 6 versus 8 hours) were not clinically significant.,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[ng] / [ml],28.86,200809,DB00327,Hydromorphone
,25653563,maximum plasma concentration (Cmax,Differences (fed versus fasted) in hydrocodone mean maximum plasma concentration (Cmax; 28.86 versus 22.74 ng/mL) and median time to Cmax (tmax; 6 versus 8 hours) were not clinically significant.,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[ng] / [ml],22.74,200810,DB00327,Hydromorphone
,25653563,time to Cmax (tmax,Differences (fed versus fasted) in hydrocodone mean maximum plasma concentration (Cmax; 28.86 versus 22.74 ng/mL) and median time to Cmax (tmax; 6 versus 8 hours) were not clinically significant.,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),h,6,200811,DB00327,Hydromorphone
,25653563,time to Cmax (tmax,Differences (fed versus fasted) in hydrocodone mean maximum plasma concentration (Cmax; 28.86 versus 22.74 ng/mL) and median time to Cmax (tmax; 6 versus 8 hours) were not clinically significant.,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),h,8,200812,DB00327,Hydromorphone
,25653563,AUC0-t,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[h·ng] / [ml],878,200813,DB00327,Hydromorphone
,25653563,AUC0-t,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[h·ng] / [ml],832,200814,DB00327,Hydromorphone
,25653563,Frel,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),%,105,200815,DB00327,Hydromorphone
,25653563,Cmax,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[ng] / [ml],51.8,200816,DB00327,Hydromorphone
,25653563,Cmax,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[ng] / [ml],46.3,200817,DB00327,Hydromorphone
,25653563,tmax,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),h,5.44,200818,DB00327,Hydromorphone
,25653563,tmax,Administration of 20% alcohol with HC-ER 50 mg did not increase systemic exposure relative to 0% alcohol (AUC0-t 878 versus 832 ng · h/mL; Frel 105%) or result in clinically meaningful changes in Cmax (51.8 versus 46.3 ng/mL) or tmax (5.44 versus 6.16 hours).,"Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),h,6.16,200819,DB00327,Hydromorphone
,25653563,AUC0-t,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[h·ng] / [ml],"1,008",200820,DB00327,Hydromorphone
,25653563,AUC0-t,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[h·ng] / [ml],832,200821,DB00327,Hydromorphone
,25653563,Frel,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),%,120,200822,DB00327,Hydromorphone
,25653563,Cmax,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[ng] / [ml],109,200823,DB00327,Hydromorphone
,25653563,Cmax,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),[ng] / [ml],46.3,200824,DB00327,Hydromorphone
,25653563,tmax,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),h,2.43,200825,DB00327,Hydromorphone
,25653563,tmax,"Administration with 40% alcohol increased AUC0-t (1,008 ng · h/mL versus 832 ng · h/mL; Frel 120%) and Cmax (109 versus 46.3 ng/mL), and shortened tmax (2.43 versus 6.16 hours).","Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25653563/),h,6.16,200826,DB00327,Hydromorphone
,26535968,Tmax,"Following a single dose of hydrocodone-ER, Tmax was prolonged to approximately 6 hours at all dose levels of hydrocodone-ER compared with 2.9 hours for the IR formulation.",A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26535968/),h,6,204674,DB00327,Hydromorphone
,26535968,Tmax,"Following a single dose of hydrocodone-ER, Tmax was prolonged to approximately 6 hours at all dose levels of hydrocodone-ER compared with 2.9 hours for the IR formulation.",A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26535968/),h,2.9,204675,DB00327,Hydromorphone
,25255074,clearance,"After intravenous administration, the median clearance and terminal half-life were 37.7 (range, 33.7 to 47.1) mL/kg/min and 142 (range, 131 to 218) min, respectively.",Pharmacokinetics of hydromorphone after intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25255074/),[ml] / [kg·min],37.7,209371,DB00327,Hydromorphone
,25255074,terminal half-life,"After intravenous administration, the median clearance and terminal half-life were 37.7 (range, 33.7 to 47.1) mL/kg/min and 142 (range, 131 to 218) min, respectively.",Pharmacokinetics of hydromorphone after intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25255074/),min,142,209372,DB00327,Hydromorphone
,25255074,elimination half-life,The median (range) elimination half-life after intramuscular administration was 81.5 (77.2 to 92.5) min.,Pharmacokinetics of hydromorphone after intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25255074/),min,81.5,209373,DB00327,Hydromorphone
,25255074,intramuscular bioavailability,"Median intramuscular bioavailability was 92% (range, 75% to 104%).",Pharmacokinetics of hydromorphone after intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25255074/),%,92,209374,DB00327,Hydromorphone
,17270058,Tmax,Median Tmax (12.0-16.0 hours) and mean t1/2 (10.6-11.0 hours) were found to be independent of dose.,Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17270058/),h,12.0-16.0,215475,DB00327,Hydromorphone
,17270058,t1/2,Median Tmax (12.0-16.0 hours) and mean t1/2 (10.6-11.0 hours) were found to be independent of dose.,Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17270058/),h,10.6-11.0,215476,DB00327,Hydromorphone
,23601353,Cmax,Cmax for ASG-oxymorphone was 7.5 ng mL(-1) ; Cmax for ASG-hydromorphone was 5.7 ng mL(-1) .,Pharmacokinetics of ammonium sulfate gradient loaded liposome-encapsulated oxymorphone and hydromorphone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23601353/),[ng] / [ml],7.5,218925,DB00327,Hydromorphone
,23601353,Cmax,Cmax for ASG-oxymorphone was 7.5 ng mL(-1) ; Cmax for ASG-hydromorphone was 5.7 ng mL(-1) .,Pharmacokinetics of ammonium sulfate gradient loaded liposome-encapsulated oxymorphone and hydromorphone in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23601353/),[ng] / [ml],5.7,218926,DB00327,Hydromorphone
,28345745,conversion to OC,Incubation at 80°C for 24 hours in vinegar or vodka produced a conversion to OC of 6 percent.,"In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28345745/),%,6,219178,DB00327,Hydromorphone
,28345745,half-life,Incubation with trypsin at 37°C converted PF614 approximately stoichiometric to OC with half-life of 4 hours.,"In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28345745/),h,4,219179,DB00327,Hydromorphone
,6204757,ED50,"Acutely, oxymorphazone (ED50, 0.6 mg/kg, sc) was approximately half as potent as oxymorphone (ED50, 0.3 mg/kg, sc) in the tail-flick assay.",Oxymorphazone: a long-acting opiate analgesic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6204757/),[mg] / [kg],0.3,225561,DB00327,Hydromorphone
,23958818,CL1,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),[l] / [min],1.01,234602,DB00327,Hydromorphone
,23958818,V1,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),l,3.35,234603,DB00327,Hydromorphone
,23958818,CL2,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),[l] / [min],1.47,234604,DB00327,Hydromorphone
,23958818,V2,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),l,13.9,234605,DB00327,Hydromorphone
,23958818,CL3,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),[l] / [min],1.41,234606,DB00327,Hydromorphone
,23958818,V3,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),l,145,234607,DB00327,Hydromorphone
,23958818,half-time,"The elimination clearance decreased by 43% between the age of 40 and 80 yr, and simulations demonstrated that context-sensitive half-time increased from 26 to 84 min in 40- and 80-yr-old subjects, respectively.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),min,26,234608,DB00327,Hydromorphone
,23958818,half-time,"The elimination clearance decreased by 43% between the age of 40 and 80 yr, and simulations demonstrated that context-sensitive half-time increased from 26 to 84 min in 40- and 80-yr-old subjects, respectively.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),min,84,234609,DB00327,Hydromorphone
>,18360598,bioavailability,The bioavailability of oxycodone is >60% and the bioavailability of morphine is 20%.,Oxycodone controlled release in cancer pain management. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360598/),%,60,238891,DB00327,Hydromorphone
,18360598,bioavailability,The bioavailability of oxycodone is >60% and the bioavailability of morphine is 20%.,Oxycodone controlled release in cancer pain management. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360598/),%,20,238892,DB00327,Hydromorphone
,18360598,half-life,"There is a rapid phase with a mean half-life of 37 min, accounting for 38% of the dose, and a slow phase with a half-life of 6.2 h, which accounts for the residual 62%.",Oxycodone controlled release in cancer pain management. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360598/),min,37,238893,DB00327,Hydromorphone
,18360598,half-life,"There is a rapid phase with a mean half-life of 37 min, accounting for 38% of the dose, and a slow phase with a half-life of 6.2 h, which accounts for the residual 62%.",Oxycodone controlled release in cancer pain management. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18360598/),h,6.2,238894,DB00327,Hydromorphone
,24236993,pKa,"It has been argued that absorption of buprenorphine through the buccal mucosa is high, in part due to its pKa of 8.24.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),,8.24,243813,DB00327,Hydromorphone
,24236993,pKa,"Morphine, methadone, hydromorphone, and oxymorphone have a pKa between 8 and 9.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),,8 and 9,243814,DB00327,Hydromorphone
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,36.6,243815,DB00327,Hydromorphone
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,44.2,243816,DB00327,Hydromorphone
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,22.4,243817,DB00327,Hydromorphone
,24236993,bioavailability,"Mean ± SE (range) bioavailability was 36.6 ± 5.2 (12.7-49.5), 44.2 ± 7.9 (18.7-70.5), 22.4 ± 6.9 (6.4-43.4), and 18.8 ± 2.0 (12.9-23.5)% for buccal administration of morphine, methadone, hydromorphone, and oxymorphone, respectively.","Bioavailability of morphine, methadone, hydromorphone, and oxymorphone following buccal administration in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24236993/),%,18.8,243818,DB00327,Hydromorphone
,2453226,elimination half-life,"After i.v. administration the following pharmacokinetic parameters were found: elimination half-life 2.36 +/- 0.5 h, hepatic extraction ratio 0.51, apparent volume of distribution 2.9 +/- 1.3 L kg-1 and volume of central compartment 0.23 +/- 0.2 L kg-1.","Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453226/),h,2.36,247787,DB00327,Hydromorphone
,2453226,hepatic extraction ratio,"After i.v. administration the following pharmacokinetic parameters were found: elimination half-life 2.36 +/- 0.5 h, hepatic extraction ratio 0.51, apparent volume of distribution 2.9 +/- 1.3 L kg-1 and volume of central compartment 0.23 +/- 0.2 L kg-1.","Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453226/),,0.51,247788,DB00327,Hydromorphone
,2453226,apparent volume of distribution,"After i.v. administration the following pharmacokinetic parameters were found: elimination half-life 2.36 +/- 0.5 h, hepatic extraction ratio 0.51, apparent volume of distribution 2.9 +/- 1.3 L kg-1 and volume of central compartment 0.23 +/- 0.2 L kg-1.","Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453226/),[l] / [kg],2.9,247789,DB00327,Hydromorphone
,2453226,volume of central compartment,"After i.v. administration the following pharmacokinetic parameters were found: elimination half-life 2.36 +/- 0.5 h, hepatic extraction ratio 0.51, apparent volume of distribution 2.9 +/- 1.3 L kg-1 and volume of central compartment 0.23 +/- 0.2 L kg-1.","Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453226/),[l] / [kg],0.23,247790,DB00327,Hydromorphone
,2453226,absolute bioavailability,"The absolute bioavailability after peroral administration was 50.7 +/- 29.8 per cent, and that after rectal administration was 33 +/- 22 per cent.","Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453226/),%,50.7,247791,DB00327,Hydromorphone
,2453226,absolute bioavailability,"The absolute bioavailability after peroral administration was 50.7 +/- 29.8 per cent, and that after rectal administration was 33 +/- 22 per cent.","Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453226/),%,33,247792,DB00327,Hydromorphone
,2452249,tail-flick latencies,"In contrast, OxyPNPH at 25 mg/kg elevated tail-flick latencies from 2 to over 8 sec after 10 hr.",Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,2,250726,DB00327,Hydromorphone
,2452249,tail-flick latencies,"In contrast, OxyPNPH at 25 mg/kg elevated tail-flick latencies from 2 to over 8 sec after 10 hr.",Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,over,250727,DB00327,Hydromorphone
,2452249,tail-flick latencies,"In contrast, OxyPNPH at 25 mg/kg elevated tail-flick latencies from 2 to over 8 sec after 10 hr.",Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,8,250728,DB00327,Hydromorphone
,2452249,latencies,The 50-mg/kg dose elevated latencies to approximately 5 sec after 24 hr.,Irreversible opiate agonists and antagonists. Analgesic actions of 14-hydroxydihydromorphinone hydrazones. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452249/),s,5,250729,DB00327,Hydromorphone
,30074252,standard curve,The standard curve ranged from 1 to 500 ng/mL.,Development of a method for the determination of hydromorphone in plasma by LC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30074252/),[ng] / [ml],1 to 500,251982,DB00327,Hydromorphone
,6183551,ED50's,"Acutely, oxymorphazone was less potent in vivo than oxymorphone (ED50's of 0.8 and 0.4 mg/kg, respectively).",Receptor binding and analgesic properties of oxymorphazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6183551/),[mg] / [kg],0.8,253392,DB00327,Hydromorphone
,6183551,ED50's,"Acutely, oxymorphazone was less potent in vivo than oxymorphone (ED50's of 0.8 and 0.4 mg/kg, respectively).",Receptor binding and analgesic properties of oxymorphazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6183551/),[mg] / [kg],0.4,253393,DB00327,Hydromorphone
,26556729,plasma target concentrations,"Postoperatively, hydromorphone was applied intravenously during three sequential periods: (1) as TCI with plasma target concentrations of 1 to 2 ng/ml until extubation; (2) as TCI-PCA with plasma target concentrations between 0.8 and 10 ng/ml during the following 6 to 8 h; and (3) thereafter as PCA with a bolus dose of 0.2 mg until the next morning.",Patient-controlled Analgesia with Target-controlled Infusion of Hydromorphone in Postoperative Pain Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556729/),[ng] / [ml],1 to 2,253494,DB00327,Hydromorphone
,26556729,plasma target concentrations,"Postoperatively, hydromorphone was applied intravenously during three sequential periods: (1) as TCI with plasma target concentrations of 1 to 2 ng/ml until extubation; (2) as TCI-PCA with plasma target concentrations between 0.8 and 10 ng/ml during the following 6 to 8 h; and (3) thereafter as PCA with a bolus dose of 0.2 mg until the next morning.",Patient-controlled Analgesia with Target-controlled Infusion of Hydromorphone in Postoperative Pain Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556729/),[ng] / [ml],0.8 and 10,253495,DB00327,Hydromorphone
,26556729,maximum plasma target concentration,The maximum plasma target concentration during TCI-PCA was 2.3 ng/ml (0.9 to 7.0 ng/ml).,Patient-controlled Analgesia with Target-controlled Infusion of Hydromorphone in Postoperative Pain Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556729/),[ng] / [ml],2.3,253496,DB00327,Hydromorphone
,26556729,EC50,The EC50 of hydromorphone for NRS of 4 or less was 4.1 ng/ml (0.6 to 12.8 ng/ml).,Patient-controlled Analgesia with Target-controlled Infusion of Hydromorphone in Postoperative Pain Therapy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556729/),[ng] / [ml],4.1,253497,DB00327,Hydromorphone
,31959534,terminal half-life (t1/2),"The mean ± SD hydromorphone terminal half-life (t1/2), clearance and volume of distribution of H-IV were 19 ± 8 minutes, 79 ± 12.9 mL minute⁻1 kg⁻1 and 1125 ± 309 mL kg⁻1.",Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),min,19,266086,DB00327,Hydromorphone
,31959534,clearance,"The mean ± SD hydromorphone terminal half-life (t1/2), clearance and volume of distribution of H-IV were 19 ± 8 minutes, 79 ± 12.9 mL minute⁻1 kg⁻1 and 1125 ± 309 mL kg⁻1.",Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),kg⁻1·minute⁻1·ml,79,266087,DB00327,Hydromorphone
,31959534,volume of distribution,"The mean ± SD hydromorphone terminal half-life (t1/2), clearance and volume of distribution of H-IV were 19 ± 8 minutes, 79 ± 12.9 mL minute⁻1 kg⁻1 and 1125 ± 309 mL kg⁻1.",Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),kg⁻1·ml,1125,266088,DB00327,Hydromorphone
,31959534,t1/2,The t1/2 was 26.7 ± 9.25 minutes for H-IM.,Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),min,26.7,266089,DB00327,Hydromorphone
,31959534,Area under the curve,"Area under the curve was 518 ± 87.5 and 1128 ± 810 minute ng mL⁻1 for H-IV and H-IM, respectively.",Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),min·ml⁻1·ng,518,266090,DB00327,Hydromorphone
,31959534,Area under the curve,"Area under the curve was 518 ± 87.5 and 1128 ± 810 minute ng mL⁻1 for H-IV and H-IM, respectively.",Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),min·ml⁻1·ng,1128,266091,DB00327,Hydromorphone
,31959534,bioavailability,The IM bioavailability was 217%.,Pharmacokinetics and pharmacodynamics of hydromorphone after intravenous and intramuscular administration in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31959534/),%,217,266092,DB00327,Hydromorphone
,32702184,minimum effective analgesic concentration,"Monte Carlo simulations based on the final pharmacokinetic model determined optimal patient-controlled analgesia parameters to achieve a target of 20 ng/mL (as the median effective analgesic concentration), using minimum effective analgesic concentration of 4 ng/mL as a proxy for patient-controlled analgesia dose demand, and not exceeding the defined safe upper threshold of 40 ng/mL.",Hydromorphone population pharmacokinetics in pediatric surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32702184/),[ng] / [ml],4,270978,DB00327,Hydromorphone
,32702184,systemic clearance,"Allometrically scaledpharmacokinetic parameter estimates (per 70 kg), systemic clearance (0.748 L/min), volume of distribution (33 L), peripheral clearance (1.57 L/min), and peripheral volume of distribution (146 L) were similar to reported adult parameter estimates.",Hydromorphone population pharmacokinetics in pediatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32702184/),[l] / [min],0.748,270979,DB00327,Hydromorphone
,32702184,volume of distribution,"Allometrically scaledpharmacokinetic parameter estimates (per 70 kg), systemic clearance (0.748 L/min), volume of distribution (33 L), peripheral clearance (1.57 L/min), and peripheral volume of distribution (146 L) were similar to reported adult parameter estimates.",Hydromorphone population pharmacokinetics in pediatric surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32702184/),l,33,270980,DB00327,Hydromorphone
,32702184,peripheral clearance,"Allometrically scaledpharmacokinetic parameter estimates (per 70 kg), systemic clearance (0.748 L/min), volume of distribution (33 L), peripheral clearance (1.57 L/min), and peripheral volume of distribution (146 L) were similar to reported adult parameter estimates.",Hydromorphone population pharmacokinetics in pediatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32702184/),[l] / [min],1.57,270981,DB00327,Hydromorphone
,32702184,peripheral volume of distribution,"Allometrically scaledpharmacokinetic parameter estimates (per 70 kg), systemic clearance (0.748 L/min), volume of distribution (33 L), peripheral clearance (1.57 L/min), and peripheral volume of distribution (146 L) were similar to reported adult parameter estimates.",Hydromorphone population pharmacokinetics in pediatric surgical patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32702184/),l,146,270982,DB00327,Hydromorphone
,23973378,plasma clearance,"The mean plasma clearance of methadone was 19.9 ± 8.5 mL/min (± SD) compared with 105.7 ± 8.3 mL/min for HM, a difference of 85.7 mL/min (95% confidence interval 61.9 to 109.1).",Intradialytic clearance of opioids: methadone versus hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23973378/),[ml] / [min],19.9,271827,DB00327,Hydromorphone
,23973378,plasma clearance,"The mean plasma clearance of methadone was 19.9 ± 8.5 mL/min (± SD) compared with 105.7 ± 8.3 mL/min for HM, a difference of 85.7 mL/min (95% confidence interval 61.9 to 109.1).",Intradialytic clearance of opioids: methadone versus hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23973378/),[ml] / [min],105.7,271828,DB00327,Hydromorphone
,30930095,terminal half-life (t1/2),"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),min,18.1,272911,DB00327,Hydromorphone
,30930095,systemic clearance,"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),min,34.0,272912,DB00327,Hydromorphone
,30930095,systemic clearance,"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),min,41.3,272913,DB00327,Hydromorphone
,30930095,systemic clearance,"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg·min],66.6,272914,DB00327,Hydromorphone
,30930095,systemic clearance,"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg·min],550.0,272915,DB00327,Hydromorphone
,30930095,systemic clearance,"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg·min],92.7,272916,DB00327,Hydromorphone
,30930095,systemic clearance,"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg],1118,272917,DB00327,Hydromorphone
,30930095,apparent volume of distribution at steady state (Vdss),"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg·min],550.0,272918,DB00327,Hydromorphone
,30930095,apparent volume of distribution at steady state (Vdss),"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg·min],92.7,272919,DB00327,Hydromorphone
,30930095,apparent volume of distribution at steady state (Vdss),"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg],1118,272920,DB00327,Hydromorphone
,30930095,apparent volume of distribution at steady state (Vdss),"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg],1460,272921,DB00327,Hydromorphone
,30930095,apparent volume of distribution at steady state (Vdss),"Mean (± standard deviation) hydromorphone terminal half-life (t1/2), systemic clearance and apparent volume of distribution at steady state (Vdss) were 18.1 ± 18.6, 34.0 ± 12.8, and 41.3 ± 32.5 minutes, 66.6 ± 5.3, 550.0 ± 76.4, and 92.7 ± 13.9 mL kg-1 minute-1, and 1118 ± 369, 1460 ± 325 and 2242 ± 950 mL kg-1 for treatments LD, MD and HD, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),[ml] / [kg],2242,272922,DB00327,Hydromorphone
,30930095,HR,"HR was elevated above baseline in treatments LD, MD and HD, extending to 30, 15 and 105 minutes after treatment, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),,30,272923,DB00327,Hydromorphone
,30930095,HR,"HR was elevated above baseline in treatments LD, MD and HD, extending to 30, 15 and 105 minutes after treatment, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),,15,272924,DB00327,Hydromorphone
,30930095,HR,"HR was elevated above baseline in treatments LD, MD and HD, extending to 30, 15 and 105 minutes after treatment, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),,105,272925,DB00327,Hydromorphone
,30930095,Respiratory rate,"Respiratory rate was elevated above baseline in treatments MD and HD from 30 to 195 minutes and from 45 to 480 minutes after treatment, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),min,30 to 195,272926,DB00327,Hydromorphone
,30930095,Respiratory rate,"Respiratory rate was elevated above baseline in treatments MD and HD from 30 to 195 minutes and from 45 to 480 minutes after treatment, respectively.",The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30930095/),min,45 to 480,272927,DB00327,Hydromorphone
